Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does EVOLOCUMAB Cause Influenza like illness? 3,036 Reports in FDA Database

Lower Your Cholesterol — The Natural Way

The Oxidized Cholesterol Strategy: a science-backed plan for heart health.

See the Strategy

According to the FDA Adverse Event Reporting System (FAERS), 3,036 reports of Influenza like illness have been filed in association with EVOLOCUMAB (REPATHA). This represents 2.0% of all adverse event reports for EVOLOCUMAB.

3,036
Reports of Influenza like illness with EVOLOCUMAB
2.0%
of all EVOLOCUMAB reports
9
Deaths
121
Hospitalizations

How Dangerous Is Influenza like illness From EVOLOCUMAB?

Of the 3,036 reports, 9 (0.3%) resulted in death, 121 (4.0%) required hospitalization, and 8 (0.3%) were considered life-threatening.

Is Influenza like illness Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for EVOLOCUMAB. However, 3,036 reports have been filed with the FAERS database.

What Other Side Effects Does EVOLOCUMAB Cause?

Device difficult to use (31,807) Drug dose omission by device (23,957) Wrong technique in product usage process (21,664) Accidental exposure to product (16,160) Injection site pain (9,988) Product storage error (6,606) Back pain (5,254) Myalgia (5,061) Drug dose omission (4,914) Injection site bruising (4,409)

What Other Drugs Cause Influenza like illness?

INTERFERON BETA-1A (4,475) OFATUMUMAB (2,727) ADALIMUMAB (2,287) PEGINTERFERON BETA-1A (1,431) ETANERCEPT (1,383) RIBAVIRIN (1,297) METHOTREXATE (1,295) PEGINTERFERON ALFA-2A (1,208) INTERFERON BETA-1B (1,042) SECUKINUMAB (1,039)

Which EVOLOCUMAB Alternatives Have Lower Influenza like illness Risk?

EVOLOCUMAB vs EXELON EVOLOCUMAB vs EXEMESTANE EVOLOCUMAB vs EXENATIDE EVOLOCUMAB vs EXFORGE EVOLOCUMAB vs EXJADE

Related Pages

EVOLOCUMAB Full Profile All Influenza like illness Reports All Drugs Causing Influenza like illness EVOLOCUMAB Demographics